SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Growth Hormone SecretagoguesResearch peptide

Ipamorelin

A selective growth-hormone-releasing peptide that produces clean GH pulses without major cortisol or prolactin spikes.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Ipamorelin is a pentapeptide ghrelin-receptor agonist (GHRP) designed to stimulate the pituitary to release growth hormone in pulses similar to natural physiology.

Source
  • Synthesized in research laboratories
Forms
  • Subcutaneous injection

Mechanism of action

Activates the GHS-R1a receptor on pituitary somatotrophs, triggering pulsatile growth-hormone release without strongly affecting cortisol or prolactin.

Pathways
  • · GHS-R1a → GH release
  • · Downstream IGF-1 production in liver
Receptors
  • · Growth hormone secretagogue receptor (GHS-R1a)
Hormones
  • · Growth hormone
  • · IGF-1

How it acts on the body

Ipamorelin mimics ghrelin's effect at the pituitary but is selective for the GHS-R1a receptor on somatotrophs. That selectivity is the point — older GHRPs (GHRP-2, GHRP-6, hexarelin) also activate ACTH and prolactin pathways, producing cortisol surges and water retention. Ipamorelin largely avoids that, which is why it's the GHRP that most resembles a 'clean' GH pulse.

The pulse itself matters more than total GH exposure. The body interprets sharp, brief pulses (like those in stage-III sleep) as a youthful endocrine signal that promotes lipolysis, lean-tissue maintenance, and IGF-1 production by the liver. Sustained GH elevation — as seen with exogenous HGH — desensitizes receptors and disrupts insulin signaling. Ipamorelin works with the body's pulsatile rhythm rather than overriding it.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Growth hormone (GH)Increases
Triggers a brief, sharp GH pulse 15–60 minutes after dosing, mimicking natural nocturnal release.
IGF-1Increases
Liver-produced IGF-1 rises secondarily; this carries most of GH's anabolic and recovery effects.
CortisolStabilizes
Minimal effect — a defining advantage over older GHRPs like GHRP-6.
ProlactinStabilizes
Negligible elevation, so it lacks the libido- and mood-blunting effects of less-selective GHRPs.
Insulin sensitivityDecreases
Sustained GH/IGF-1 elevation can mildly reduce insulin sensitivity over weeks; usually reversible.
Ghrelin (appetite)Modulates
Activates the ghrelin receptor without raising ghrelin itself, producing transient hunger.

Effects on the body

Increases
Pulsatile growth hormone release
Supports
Lean mass and recovery
Optimizes
Deep sleep architecture

Organ system effects

Skeletal Muscle

Improves recovery and lean-tissue maintenance with consistent use.

Endocrine

Targets the somatotropic axis without strong cortisol or prolactin response.

Brain & CNS

GH and IGF-1 elevations correlate with sleep quality and slow-wave sleep duration.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Better sleep quality and recovery reported anecdotally
  • Improved body composition over weeks of consistent use
  • May support skin and connective-tissue quality via IGF-1

Potential side effects

Common
  • · Transient head rush or flushing
  • · Mild hunger spike
  • · Injection-site irritation
Rare
  • · Numbness or tingling in extremities
  • · Lightheadedness
Serious
  • · Long-term effects on insulin sensitivity are not fully characterized

Drug interactions

Glucocorticoids
May blunt GH response.
moderate
Insulin / sulfonylureas
GH can reduce insulin sensitivity over time.
moderate

Pairing context

Often combined with
  • CJC-1295 (without DAC)
    Common research pairing for synergistic GH release.
Avoid combining with
  • Active malignancy
    GH/IGF-1 axis stimulation is generally avoided.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.